Xavier Leleu

Research interests

Publications

• Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2312054

• Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2303379

• Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00592-4

• Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00592-4

• Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00466-6

• Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00128-5

• Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(20)30756-7

• Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

  The Lancet · 2020 · https://doi.org/10.1016/s0140-6736(20)32292-3

• Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)32556-5

• Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)31240-1

• Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)32556-5

• Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1817249

• Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel

  Journal of Hematology & Oncology · 2018 · https://doi.org/10.1186/s13045-017-0549-1

• Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

  Leukemia · 2017 · https://doi.org/10.1038/leu.2017.138

• Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1611750

• Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

  The Lancet Haematology · 2016 · https://doi.org/10.1016/s2352-3026(16)00021-1

• Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2014.59.1503

• International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70442-5

• International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.47.7901

• Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

  New England Journal of Medicine · 2012 · https://doi.org/10.1056/nejmoa1114138

• Response assessment in W aldenström macroglobulinaemia: update from the VI th I nternational W orkshop

  British Journal of Haematology · 2012 · https://doi.org/10.1111/bjh.12102

• Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

  The Lancet Oncology · 2011 · 10.1016/s1470-2045(11)70081-x

• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

  Leukemia · 2011 · https://doi.org/10.1038/leu.2011.196

• Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2010.28.3945

• High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

  New England Journal of Medicine · 2007 · https://doi.org/10.1056/nejmoa070484

Current projects

No projects listed.